LOS ANGELES, CA / ACCESSWIRE / July 21, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Juno Therapeutics Inc. (“Juno” or the “Company”) (NASDAQ: JUNO) concerning possible violations of federal securities laws between June 4, 2016 and July 7, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the September 12, 2016 lead plaintiff motion
deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, the Company failed to disclose that a patient died during a clinical trial for its product candidate in May 2016. Juno was thus trading at artificially inflated prices and some insiders participated in heavy selling of shares until July 7, 2016. On July 7, 2016 the Company announced the May 2016 death and two additional deaths during clinical trial, and the Food & Drug Administration put a hold on the trial. After the release of this news, shares of Juno dropped in value significantly.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442686

CALGARY, AB / ACCESSWIRE / July 21, 2016 / NovaTeqni Corporation (TSXV: NTQ) (“NovaTeqni” or the “Corporation”), announces that it has made application to the TSX Venture Exchange (the “Exchange“) to extend the term of 454,747 common share purchase warrants (the “Warrants“) that were issued under the Company’s private placement of units completed on July 24, 2015 and August 26, 2015. The Warrants that are the subject of the application have an exercise price of $1.00 per common share and are set to expire on July 24, 2016 (as to 396,247 Warrants) and August 26, 2016 (as to 58,500 Warrants). None of the Warrants are held by Insiders of the Corporation. The Corporation has applied for consent to extend the term of the Warrants from 12 months to 24 months from the respective dates of the original issuance of the Warrants in accordance with Exchange policies.

About NovaTeqni

NovaTeqni is a technology based company that is focusing on biometrics and secure payment technologies. Using its management experience and developed intellectual property, NovaTeqni provides solutions and products for voter validation, voter registration, financial transactions and biometric solutions. Using the its platform of products, NovaTeqni can provide clients with custom solutions for their particular industry. NovaTeqni has corporate offices in Calgary, Alberta, sales offices in Norfolk, Virginia, development in Johannesburg, South Africa and manufacturing in Hong Kong.

For further information, please contact Gerhard Mynhardt, Chief Executive Officer of the Corporation, by email at info@novateqni.com.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: NovaTeqni Corporation

ReleaseID: 442685

IRVINE, CA / ACCESSWIRE / July 21, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Lipocine Inc. (“Lipocine” or the “Company”) (NASDAQ: LPCN). Investors who purchased or otherwise acquired shares between June 30, 2015 and June 28, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the August
30, 2016 lead plaintiff motion deadline.

If you purchased shares of Lipocine during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company made false and/or misleading statements and/or failed to disclose that: Lipocine’s filing of its New Drug Application to the U.S. Food and Drug Administration for LPCN 1021 (the Company’s lead product candidate) contained deficiencies; and as a result, Lipocine’s statements about its business and operations were false and misleading and/or lacked a reasonable basis. When this information was released, investors suffered losses.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442683

LOS ANGELES, CA / ACCESSWIRE / July 21, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Unilife Corporation (“Unilife” or the “Company”) (NASDAQ: UNIS) concerning possible violations of federal securities laws between February 3, 2014 and May 23, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 25, 2016 lead plaintiff motion
deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, during the Class Period, the Company made false and misleading statements and/or failed to disclose that: the Company’s former Chief Executive Officer and former Chairman of the Board of Directors had violated the Company’s policies and procedures, and engaged in violations of law and regulation; that the Company lacked adequate internal controls over accounting and financial reporting; and as a result of the above, Unilife could not file its Quarterly Report on Form 10-Q by the filing deadline. Upon release of this news, the Company’s stock price dropped.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442684

LOS ANGELES, CA / ACCESSWIRE / July 21, 2016 / Lundin Law PC announces that a class action lawsuit has been filed against Halyard Health, Inc. (“Halyard” or the “Company”) (NYSE: HYH) on behalf of investors who purchased or otherwise acquired shares (1) on or after February 25, 2013 and subsequently received Halyard securities pursuant to the spin-off of Kimberly-Clark Corporation (NYSE: KMB) from Halyard, effective as of October 31, 2014; and/or (2) purchased or otherwise acquired Halyard securities between October 21, 2014 and April 29, 2016, both dates inclusive (collectively, the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws.

Investors who purchased or otherwise acquired shares during one of those periods should contact the Firm in advance of the August 29, 2016 lead plaintiff
motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, the Company issued misleading statements and/or failed to disclose that: the Company’s MICROCOOL surgical gowns consistently failed effectiveness tests and failed to meet industry standards; and Kimberly-Clark and Halyard had knowingly provided defective MICROCOOL surgical gowns to U.S. workers during the Ebola crisis. When this news was released, shares of the Halyard stock dropped in value.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442682

Williamson Promoted To New Post from Director Industry Relations and Strategic Initiatives

WASHINGTON, DC / ACCESSWIRE / July 21, 2016 / The Electronic Retailing Association (ERA) (www.retailing.org) has promoted Jennifer Williamson to the position of Vice President, Industry Relations and Strategy from her previous post as Director Industry Relations and Strategic Initiatives, it was announced by Chris Reinmuth, President and Chief Executive officer.

In her new position, Williamson will oversee ERA’s external publishing activities, Board Relations, Membership Strategic Planning, planning for the annual Moxie Awards Event and Volunteer Engagement Program.

A nonprofit executive with 20 years of experience working with regional and national nonprofit organizations and associations, Williamson has held senior-level positions with the Northern Virginia Technology Council and the National Risk Retention Association, and was recently appointed to American Society of Association Executives (ASAE) Small Staff Association Committee. In addition, Williamson has provided staff support and leadership as a volunteer with several nonprofit Boards and is currently President of the Board of Directors of Artomatic, a nonprofit arts organization. She also volunteers her time on a weekly basis at Virginia Hospital Center in Arlington, Virginia visiting patients with her dog as a therapy animal team.

Williamson earned her BS from James Madison University, a MS in Nonprofit & Association Management and an MBA from the University of Maryland. She earned the CAE (Certified Association Executive) credential from the American Society of Association Executives in 2004 and will be a 2016 graduate of the US Chamber of Commerce Foundation’s Institute for Organization Management where she will earn the IOM credential.

“Jennifer has served ERA with total dedication the Association and its membership. Her enormous contributions over her years to ERA have played a pivotal role in the Association’s growth. We look forward to continuing to benefit from Jennifer’s commitment and creativity as she moves into her expanded senior executive role,” said Reinmuth.

About the Electronic Retailing Association:

The Electronic Retailing Association (ERA) serves as the exclusive trade association representing the $350 billion direct-to-consumer marketplace. ERA membership spans the globe to encompass all levels of direct marketers, from start-up companies to global leaders that employ the power of direct response to market across all platforms including television, digital media and radio to achieve a consumer-direct, measurable and accountable response. In addition to helping grow its members’ business opportunities and profitability as a major resource for networking, business tools and information, ERA is also the voice of the direct-to-consumer industry in the nation’s Capital, working daily to protect the regulatory and legislative climate in an ongoing effort to ensure direct response marketers’ ability to bring quality products and services to the consumer. Through its acclaimed self-regulatory guidelines, ERA is also dedicated to building consumer trust in direct response-marketed products and services.

CONTACT:

SSA Public Relations
Steve Syatt
steve@ssapr.com
(818) 907-0500

SOURCE: The Electronic Retailing Association

ReleaseID: 442679

IRVINE, CA / ACCESSWIRE / July 21, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Inovalon Holdings, Inc. (“Inovalon” or the “Company”) (NASDAQ: INOV). Investors who purchased or otherwise acquired shares on or about the February 12, 2015 initial public offering (“IPO”) date, are encouraged to contact the Firm prior to the August 23, 2016, lead plaintiff motion deadline.

If you purchased shares of Inovalon on or about the IPO date, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, Inovalon’s Registration Statement issued in connection with the IPO failed to disclose material facts and contained misleading and/or false statements. The Company did not disclose that it receives substantial revenues from sales in New York City and New York State, both of which were pushing to obtain more taxes from out-of-state businesses like Inovalon. The corporate tax rate increases were implemented on January 1, 2015. This increase significantly raised Inovalon’s effective tax rate, and lowered the Company’s 2015 earning potential. When this news was released, the Company’s common stock value dropped significantly, causing investors harm.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442681

IRVINE, CA / ACCESSWIRE / July 21, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against CPI Card Group, Inc. (“CPI” or the “Company”) (NASDAQ: PMTS). Investors, who purchased or otherwise acquired shares on or about the October 8, 2015 initial public offering (“IPO”) date, are encouraged to contact the Firm prior to the August
15, 2016 lead plaintiff motion deadline.

If you purchased shares of CPI on or about the IPO date, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company failed to disclose that it disseminated over 100 million more cards than its biggest customers were using in the second and third quarters of 2015. This created a huge surplus which resulted in a substantial reduction of demand for additional cards for the remainder of the 2015 fiscal year. This would likely impact CPI’s profitability and thus should have been disclosed in the Registration Statement. When this information was revealed, shares dropped in value causing investors harm.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442680

LOS ANGELES, CA / ACCESSWIRE / July 21, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Immunomedics Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU) concerning possible violations of federal securities laws between April 20, 2016 and June 2, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 8, 2016 lead plaintiff motion
deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, during the Class Period, Immunomedics issued false and misleading statements to investors and/or failed to disclose: that the Company’s abstract for antibody-drug IMMU-132 submitted to the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting contained previously disclosed results from a mid-stage study; that Immunomedics misrepresented to ASCO that the abstract contained only updated and previously undisclosed data; and that as a result of this ASCO removed the IMMU-132 presentation from the 2016 ASCO Annual Meeting schedule.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442678